Co-Authors
This is a "connection" page, showing publications co-authored by QINGLONG MIAO and ELIZABETH SHPALL.
Connection Strength
0.312
-
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell. 2024 Aug 12; 42(8):1450-1466.e11.
Score: 0.062
-
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023 07 28; 9(30):eadd6997.
Score: 0.057
-
Targeting the av integrin/TGF-? axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest. 2021 07 15; 131(14).
Score: 0.050
-
Generation of glucocorticoid-resistant SARS-CoV-2 T?cells for adoptive cell therapy. Cell Rep. 2021 07 20; 36(3):109432.
Score: 0.050
-
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res. 2021 07 01; 27(13):3744-3756.
Score: 0.049
-
A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv. 2019 12 10; 3(23):4117-4130.
Score: 0.045